1. Introduction {#sec0001}
===============

The outbreak of the 2019 novel coronavirus (COVID-19) has had a devastating global impact, causing upwards of 4 million infections and over 300,000 deaths ([@bib0020]; [@bib0044]). One ensuing consequence of COVID-19 is the substantial negative economic impact, which has resulted in loss of employment and income for millions of people worldwide ([@bib0053]). Given the devastating consequences of COVID-19, increases in psychological symptoms and disorders, including depression, anxiety, stress, worry, and substance use, among others, have been observed ([@bib0037]; [@bib0049]; [@bib0052]), and a recent report emphasizes the importance of considering substance use problems in the context of COVID-19 ([@bib0048]). Specifically, COVID-19 is hypothesized to interfere with substance use disorder treatment, causing the potential for increases in withdrawal symptoms and relapse ([@bib0014]; [@bib0035]; [@bib0046]). Further, those with substance use problems appear to be particularly vulnerable to the negative effects of COVID-19. For instance, those with opioid use disorder may be particularly vulnerable to COVID-19 respiratory symptom complications ([@bib0042]), and preliminary drug therapies for COVID-19 may be less effective for those with substance use disorders ([@bib0018]). Importantly, increases in psychological symptoms appear to be associated with exacerbated COVID-19 symptom severity and progression, such that those with greater substance use behaviors (e.g. tobacco) and worry in response to the virus are more likely to have poorer disease outcomes ([@bib0027]a; [@bib0052]). Despite initial evidence documenting these associations, the psychological impact of COVID-19 for substance use is largely unknown.

Negative reinforcement models of substance use posit that elevations in negative affect in response to disasters, including stress, worry, and anxiety, will increase motivation to use substances in an effort to lessen negative affective states (i.e. using substances to cope; [@bib0002]; [@bib0006]; [@bib0013]). Although the literature concerning substance use in the context of COVID-19 is only nascent, past research from other large-scale disasters suggests that, in general, increases in substance use are observed following disaster exposure ([@bib0019]; [@bib0033], [@bib0034]; [@bib0047]). Further, some studies have found that anxiety and post-traumatic stress disorder (PTSD) associated with disaster are associated with increases in substance use in an effort to downregulate aversive emotional states ([@bib0008]). Given the observed increases in anxiety, depression, and stress in response to the COVID-19 ([@bib0037]; [@bib0049]), individuals may similarly use substances to cope with the increased negative affect in response to the current pandemic. These maladaptive coping mechanisms sit in the larger context of COVID-19 social distancing and "stay-at-home" measures; factors that may limit opportunity for healthier emotion regulation strategies, including social interaction, physical activity, and opportunities for behavioral activation (e.g., exercise with friends at parks).

The majority of work focused on substance use in the context of disaster exposure has focused on predictors of increased substance use ([@bib0024]; [@bib0036]). Yet, there is less work that has empirically examined those who *initiate* substance use following a disaster, including COVID-19. That is, for those who did not use a substance prior to the COVID-19 outbreak, are worry and fear associated with the initiation of substance use following the outbreak? Conceptually, worry and fear are distinct constructs with different mechanisms, such that fear can exist without worry, but worry is dependent on having some level of fear ([@bib0003]; [@bib0005]; [@bib0026]). It is possible that increased COVID-19-associated worry and fear may contribute to substance use initiation, but research has not examined how individual differences in such psychological factors may differ between those who used substances before COVID-19, those who began using substances after the COVID-19 outbreak, and those who do not use substances. Further, as suggested by negative reinforcement models of substance use ([@bib0002]; [@bib0016]), using substances to cope with increased negative emotion (i.e., coping motives) may be specifically related to the initiation and maintenance of substance use problems ([@bib0022]).

The aims of the current study were twofold. First, we examined if COVID-19 worry and fear differ across three groups of substances users: abstainers, pre-COVID-19 users, and COVID-19 initiators. Substances of interest included alcohol, cigarettes, cannabis, e-cigarettes, stimulants, and opioids, as these are reported to be the most commonly used and abused substances ([@bib0032]). Second, we tested how worry and fear about COVID-19 related to coping motives for substance use. It was hypothesized that COVID-19 initiators would evince the highest levels of COVID-19-related worry and fear, and that these constructs would be associated with substance use coping motives.

2. Method {#sec0002}
=========

2.1. Participants {#sec0003}
-----------------

The present study included 160 participants (43.48% female, *M* ~age~ = 37.93 years, *SD* = 11.22). Study eligibility criteria included being 18--65 years old and having an mTurk account. Exclusion criteria included being younger than 18 or older than 65, being a non-English speaker (to ensure comprehension of the study questions), and inability to give informed, and voluntary, written consent to participant.

2.2. Measures {#sec0004}
-------------

*Demographics*. Participants provided data regarding age, sex (1 = Male, 2 = Female), gender identity, sexual orientation, educational level (1 = Less than High School to 9 = Doctorate), race, ethnicity, marital status, height, weight, and U.S. state of residence. Demographic information was used to characterize the sample whereas age and sex were included as covariates.

*COVID-19 Screening and Symptoms.* Participants were asked to provide information regarding COVID-19 diagnosis ("Have you been diagnosed with COVID-19?"), exposure to confirmed cases ("Have you been exposed to someone who has confirmed COVID-19?"), and international travel ("Have you traveled to/from an area with community spread COVID-19 within the past 3 months?"). This information was used for descriptive purposes.

*Substance Use*. Participants provided information about alcohol, cigarette, cannabis, e-cigarette, stimulant, opioid, and other drug use prior to the COVID-19 outbreak. Specifically, participants were asked, "Prior to the COVID-19 outbreak, did you use..." and responses were coded 0 = No and 1 = Yes. Participants were then asked, "Since the COVID-19 outbreak, how have your...habits changed since the virus outbreak?" Responses were scored on a 5-point scale: 0 = no change, 1 = using a little more, 2 = using a lot more, 3 = using a little less, 4 = using a lot less. Individuals who reported not using substances prior to the COVID-19 outbreak but reported using "a little more" or "a lot more" since the outbreak were considered COVID-19 initiators. Individuals who reported using a substance prior to the COVID-19 outbreak were considered pre-COVID-19 substance users, and those that reported no substance use prior to the outbreak and no change in substance use post-outbreak were considered substance abstainers.

*Substance Use Motives*. Substance use motives were measured using a modified 10-item version of the Drinking Motives Questionnaire-Revised ([@bib0012]). The modified substance use motives questionnaire was anchored to the most used substance (e.g., alcohol, cigarettes, cannabis smoking/vaping, stimulants, opioids, or other substance). Participants completed the whole measure, but only the substance use motive items assessed coping motives (4 items; "To forget your worries"; α = 0.94), rated on a 5-point Likert type scale ranging from 1 (*Almost never/never*) to 5 (*Almost always/always*), were used in the current analysis.

*COVID-19 Worry.* Informed by established measures of worry ([@bib0031]), the COVID-19 Worry Index is a 15-item measure developed by the current research team to assess worry about contracting COVID-19, related symptoms, and associated health consequences. Respondents are asked to rate their worry about each item (e.g., "I worry that I will come into contact with someone that has COVID-19."). Responses are rated on a scale ranging from 1 (*Not at all*) to 7 (*A great deal*), and responses were summed for a total score, with higher scores indicating greater COVID-19-related worry. The COVID-19 Worry Index demonstrated excellent internal consistency (α = 0.96) in the present study.

*COVID-19 Fear.* The Fear of COVID-19 Scale is a 7-item measure developed by our team and is designed to assess the extent to which respondents experience anxiety-related symptoms in response to thinking about contracting COVID-19. Example items include "My hands become clammy when I think about COVID-19" and "When watching news and stories about COVID-19 on social media, I become nervous or anxious." Responses are rated on a 5-point Likert type scale ranging from 1 (*Strongly Disagree*) to 5 (*Strongly Agree*), and responses were summed for a total score, with higher scores indicating greater COVID-19-related fear. The Fear of COVID-19 Scale demonstrated excellent internal consistency (α = 0.92) in the current study.

2.3. Procedure {#sec0005}
--------------

Participants were recruited nationally via Amazon Mechanical Turk (MTurk) between April and May 2020 for a study on the relationship between COVID-19 and mental health. Interested participants click on the link to be screened for eligibility and are then directed to the anonymous online survey. MTurk uses unique worker IDs to prevent duplicate responses. Prior to completing the survey, participants indicated that they consented to participate by checking a box, but were not required to provide a signature per IRB exemption. The survey took approximately 30 minutes to complete and consisted of a battery of questionnaires regarding COVID-19 exposure and symptoms, fear and worry about COVID-19, substance use behavior pre COVID-19 and during COVID-19, and affective states. Participants were compensated \$4.00 through their MTurk account commensurate to their participation. A number of quality assurance checks were included in the survey, including requiring participants to have a \>90% approval rate, location matching to collected IP address, and speed checks, ensuring that participants did not complete the survey in less than half the median response time. The study protocol was approved by the Institutional Review Board at the University of Houston.

2.4. Data analytic plan {#sec0006}
-----------------------

Data analyses were completed using SPSS version 25. First, descriptive, and bivariate relations were examined among study variables. Second, independent one-way, between subjects Analysis of Covariance (ANCOVA) were conducted to evaluate mean differences in (a) worry about COVID-19 and (b) fear about COVID-19 between three levels of substance use: abstainers, pre-COVID-19 substance users, and COVID-19 substance use initiators. Separate ANCOVA models were run for each substance use variable, including alcohol, cigarettes, cannabis, e-cigarettes, stimulants, and opioids for the two dependent variables. Age ([@bib0039]) and sex ([@bib0030]) were included as covariates in the ANCOVA models given their *a priori* associations with substance use variables. Partial eta squared (η~p~ ^2^) served as an index of effect size of mean differences ([@bib0040]); small = .01, medium = .06, and large = .14. Post hoc LSD tests were conducted to examine the specificity and directionality among the associations of all dependent variables across groups for significant group differences. A Bonferroni correction was employed. Based on this correction, alpha was adjusted to .004 (i.e., .05/12). Additionally, given the small and unequal sample sizes in each cell, as recommended, a strict focus on effect size (*Hedge\'s g*) was utilized ([@bib0043]; [@bib0045]). Hedge\'s g is an ideal measure of effect size, as it quantifies the mean differences while correcting for small sample sizes to reduce bias, and is recommended when sample sizes are unequal and/or fall below n=20 for each cell ([@bib0021]). Effect size guidelines for *Hedge\'s g* were: small = 0.20, medium = 0.50, and large = 0.80 ([@bib0011]). Finally, to evaluate the simultaneous predictive power of worry about COVID-19 and fear about COVID-19 on coping motives, a regression model, including all participants regardless of substance use status (the dimensional nature of the measure allowed scores of 0), was conducted. Model fit was evaluated with the *F* statistic and squared semi-partial correlations (*sr* ^2^) were used as measures of effect size.

3. Results {#sec0007}
==========

3.1. Descriptive statistics {#sec0008}
---------------------------

For participant demographic characteristics, see [Table 1](#tbl0001){ref-type="table"} . In terms of COVID-19 diagnosis, 5.8% were diagnosed with COVID-19 and most of those diagnosed (80%) reported a moderate intensity of symptoms (sick, but not admitted to the hospital for more than 24 h). Over half of the sample (57.2%) reported no pre-existing conditions. For the remainder of the sample, the following pre-existing conditions were reported: diabetes (17.3%), hypertension (13.3%), asthma (12.7%), autoimmune disease (2.3%), cardiovascular disease (2.3%), other existing medical conditions (2.3%), cerebrovascular disease (1.2%), kidney disease (1.2%), liver disease (1.2%), malignant tumor (1.2%), and respiratory disease/condition (1.2%).Table 1Participant characteristics.Table 1VariableM/n (SD/%)StateAlabama1 (0.6 %)Alaska1 (0.6 %)Arizona1 (0.6 %)Arkansas1 (0.6 %)California15 (9.3 %)Colorado6 (3.7 %)Connecticut1 (0.6 %)Florida10 (6.2 %)Georgia5 (3.1 %)Hawaii3 (1.9 %)Idaho2 (1.2 %)Illinois6 (3.7 %)Indiana9 (5.6 %)Iowa2 (1.2 %)Kansas1 (0.6 %)Kentucky3 (1.9 %)Louisiana1 (0.6 %)Maine1 (0.6 %)Maryland2 (1.2 %)Michigan2 (1.2 %)Minnesota2 (1.2 %)Mississippi1 (0.6 %)Missouri4 (2.5 %)Nebraska1 (0.6 %)Nevada4 (2.5 %)New Hampshire1 (0.6 %)New Jersey6 (3.7 %)New Mexico1 (0.6 %)New York17 (10.5%)North Carolina4 (2.5 %)Ohio4 (2.5 %)Oklahoma1 (0.6 %)Oregon1 (0.6 %)Pennsylvania9 (5.6 %)Rhode Island1 (0.6 %)South Carolina1 (0.6 %)Tennessee2 (1.2 %)Texas16 (9.9 %)Utah2 (1.2 %)Virginia4 (2.5 %)Washington5 (3.1 %)West Virginia2 (1.2 %)EducationHigh School (or Equivalent)10 (6.1%)Some College19 (11.5%)Associate\'s Degree16 (9.7%)Bachelor\'s Degree84 (50.9%)Master\'s Degree32 (19.4%)Doctoral Degree4 (2.4%)RaceWhite/Caucasian109 (65.1%)Black/African American21 (12.7%)Asian21 (12.7%)Multiracial6 (3.6%)Native American/Alaska Native4 (2.4%)Other1 (0.6%)Declined3 (1.8%)EthnicityLatinx/Hispanic34 (20.6%)Non-Latinx/Hispanic128 (77.6%)Declined3 (1.8%)

Concerning substance use, 43.1% of participants endorsed using alcohol prior to the COVID-19 outbreak, 21.9% reported using cigarettes, 12.5% reported using cannabis, 8.8% reported using e-cigarettes, 5.0% reported using stimulants, and 3.1% reported using opioids. In terms of COVID-19 substance use initiation, an additional 8.8% reported drinking alcohol since the COVID-19 outbreak, 6.9% started smoking cigarettes, 5.0% started using cannabis, 4.4% started using e-cigarettes, 5.6% started using stimulants, and 5.6% started using opioids.

3.2. Psychological risk factors {#sec0009}
-------------------------------

*Alcohol Use.* Defined alcohol use groups did not differ in mean COVID-19 worry (*F*(2,155) = 3.39, *p* =.04, *η* ^2^ = .04). *Hedge\'s g* effect size estimates indicate a small to moderate mean difference between abstainers and pre-COVID-19 users (*g* = .34), a medium to large mean difference between abstainers and COVID-19 initiators (*g*= .58), and a small mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .27). Similar findings emerged for COVID-19 fear, such that alcohol use groups did not differ in their reported COVID-19 mean scores (*F*(2,155) = 2.23, *p* =.11, *η* ^2^ = .03; see [Table 2](#tbl0002){ref-type="table"} for raw mean differences). *Hedge\'s g* effect size estimates indicate a small mean difference between abstainers and pre-COVID-19 users (*g* = .22), a medium to large mean difference between abstainers and COVID-19 initiators (*g* = .56), and a small to medium mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .38).Table 2Raw mean estimates by substance use class.Table 2Covid-19 WorryCOVID-19 FearMean*SD*Mean*SD*AlcoholAbstainer (*n*=77)51.6424.5316.976.96Pre-COVID-19 User (*n*=69)59.4922.0118.426.31COVID-19 Initiator (*n*=14)65.2915.4420.795.55CigarettesAbstainer (*n*=114)53.9223.2917.396.73Pre-COVID-19 User (*n*=35)60.5123.5718.946.39COVID-19 Initiator (*n*=11)66.3616.5420.276.00CannabisAbstainer (*n*=132)54.6924.1017.866.78Pre-COVID-19 User (*n*=20)58.2014.4616.905.16COVID-19 Initiator (*n*=8)76.5014.9121.756.88E-CigarettesAbstainer (*n*=139)55.0823.7117.536.81Pre-COVID-19 User (*n*=14)61.9321.0119.865.43COVID-19 Initiator (*n*=7)67.438.8122.002.23StimulantsAbstainer (*n*=143)54.2923.0817.526.52Pre-COVID-19 User (*n*=8)67.5020.0420.507.13COVID-19 Initiator (*n*=9)76.8913.3222.116.70OpioidsAbstainer (*n*=146)54.9023.0917.416.63Pre-COVID-19 User (*n*=5)77.8016.9524.204.21COVID-19 Initiator (*n*=9)65.5620.7622.893.30

*Cigarette Use*. For COVID-19 worry, there were no statistically significant differences by cigarette use group in the ANCOVA model (*F*(2,155) = 2.15, *p* =.12, *η* ^2^ = .03). *Hedge\'s g* effect size estimates indicate a small to medium mean difference between abstainers and pre-COVID-19 users (*g* = .28), a medium to large mean difference between abstainers and COVID-19 initiators (*g* = .54), and a small to medium mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .26). For COVID-19 fear, there were no statistically significant differences by cigarette use group (*F*(2,155) = 1.58, *p* =.21, *η* ^2^ = .02). *Hedge\'s g* effect size estimates indicated a very small mean difference between abstainers and pre-COVID-19 users (*g* = .15), a small to medium mean difference between abstainers and COVID-19 initiators (*g* = .43), and a small mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .21).

*Cannabis Use*. For COVID-19 worry, there were no statistically significant differences by cannabis use (*F*(2,155) = 3.50, *p* =.03, *η* ^2^ = .04). *Hedge\'s g* effect size estimates indicate a very small mean difference between abstainers and pre-COVID-19 users (*g* = .17), a large mean difference between abstainers and COVID-19 initiators (*g* = 1.04), and a large mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = 1.25). Additionally, for COVID-19 fear, there were no statistically significant differences by cannabis use (*F*(2,155) = 1.60, *p* =.21, *η* ^2^ = .02). *Hedge\'s g* effect size estimates indicated a very small mean difference between abstainers and pre-COVID-19 users (*g* = .15), a medium to large mean difference between abstainers and COVID-19 initiators (*g* = .57), and a large mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .85).

*E-Cigarette Use*. For COVID-19 worry, there were no statistically significant differences by e-cigarette status (*F*(2,155) = 1.39, *p* =.25, *η* ^2^ = .02). *Hedge\'s g* effect size estimates indicate a small to medium mean difference between abstainers and pre-COVID-19 users (g= .29), a medium to large mean difference between abstainers and COVID-19 initiators (*g* = .53), and a small to medium mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .30). For COVID-19 fear, there were no statistically significant differences by e-cigarette use (*F*(2,155) = 2.09, *p* =.13, *η* ^2^ = .03). *Hedge\'s g* effect size estimates indicated a small to medium mean difference between abstainers and pre-COVID-19 users (*g* = .34), a medium to large mean difference between abstainers and COVID-19 initiators (*g* = .67), and a small to medium mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .46).

*Stimulant Use*. For COVID-19 worry, there were not statistically significant differences by simulant use (*F*(2,155) = 5.40, *p* =.01, *η* ^2^ = .07). *Hedge\'s g* effect size estimates indicated a medium to large mean difference between abstainers and pre-COVID-19 users (*g* = .58), a large mean difference between abstainers and COVID-19 initiators (*g* = 1.00), and a medium to large mean difference between pre-COVID-19 users and COVID-19 initiators (*d* = .56). For COVID-19 fear, there were no significant differences by stimulant use (*F*(2,155) = 2.57, *p* =.08, *η* ^2^ = .03). *Hedge\'s g* effect size estimates indicated a small to medium mean difference between abstainers and pre-COVID-19 users (*g* = .45), a medium to large mean difference between abstainers and COVID-19 initiators (*g* = .70), and a small to medium mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .23).

*Opioid Use*. For COVID-19 worry, there were not statistically significant differences by opioid use (*F*(2,155) = 3.24, *p* =.04, *η* ^2^ = .04). *Hedge\'s g* effect size estimates indicated a large mean difference between abstainers and pre-COVID-19 users (*g* = 1.00), a small to medium mean difference between abstainers and COVID-19 initiators (*g* = .46), and a medium to large mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .63). For COVID-19 fear, there were also not statistically significant differences by opioid use status (*F*(2,155) = 5.41, *p* =.01, *η* ^2^ = .07). *Hedge\'s g* effect size estimates indicated a large mean difference between abstainers and pre-COVID-19 opioid users (*g* = 1.03), a large mean difference between abstainers and COVID-19 initiators (*g* = .84), and a small to medium mean difference between pre-COVID-19 users and COVID-19 initiators (*g* = .36).

*Substance Use Motives.* For coping motives, the model was statistically significant (*R* ^2^ = .31, *F*(2, 156) = 34.23, *p* \< .001) and worry about COVID-19 was a statistically significant predictor (*b* = .10, *se* = .02, *p* \< .001). However, COVID-19 fear was not a statistically significant predictor of coping motives (*b* = .09, *se* = .08, *p* = .23).

4. Discussion {#sec0010}
=============

Available work on COVID-19, although highly limited in scope, has suggested that the pandemic is associated with clinically significant elevations in psychiatric symptoms, including anxiety, depression, stress, and substance use ([@bib0037]). The aim of the current study was to build from past work and examine how COVID-19-related worry and fear differed between those who initiated substance use during the COVID-19 outbreak, those who used substances prior to the outbreak, and those who abstained across a variety of substances including alcohol, cigarettes, cannabis, e-cigarettes, stimulants, and opioids. Effect size magnitudes suggested differences in COVID-19-related worry and fear by substance use class.

Overall, the results generally supported hypotheses, such that, across substances, levels of COVID-19-related worry and fear were highest among those people who initiated substances during the COVID-19 pandemic compared to those who used substances prior and those who never used. Effect sizes for the mean differences indicated small to medium mean differences between the groups, with the largest differences between the COVID-19 initiators and the abstainers. Given how salient these psychological concerns are currently, it is likely that these effect sizes are clinically meaningful ([@bib0010]; [@bib0025]) and suggest that both worry and fear may be potential risk candidates for substance use initiation and maintenance during the COVID-19 pandemic. These results sit on the backdrop of other work focused on disasters suggesting that coping-oriented substance use increases after a disaster due to increased psychological distress ([@bib0019]; [@bib0047]).

Of note, for opioid use, levels of COVID-19-related worry and fear were highest for the pre-COVID-19 users compared to COVID-19 initiators and abstainers. Although these results were not in line with hypotheses, there are several plausible explanations for this finding. Past research consistently documents the short-term efficacy for opioids to dampen negative affect states ([@bib0017]). Therefore, it is possible that, for those that initiated opioids during the COVID-19 outbreak, their levels of worry and fear *are* lowest because of the acute negative affect reduction; this effect would not exist for pre-COVID-19 users due to long-term potential tolerance ([@bib0009]). It is also possible that the method by which opioids are commonly acquired (i.e. prescription from physician) is less accessible as a result of limited in-person health screening.

It is also worth noting that cannabis use appeared to be associated with the largest effects across groups. Given the widespread use (both legal and illicit) of cannabis use ([@bib0038]) as well as past work among trauma-exposed samples documenting increases in cannabis use following trauma ([@bib0004]; [@bib0015]), it may be particularly important to focus on cannabis use. Specifically, previous work suggests that traumatic event exposure may be specifically related to cannabis initiation ([@bib0050]), and that using cannabis in response to stress has been specifically linked to increased likelihood of developing a substance use disorder ([@bib0023]). These data urge further focus on cannabis use in the context of COVID-19.

In terms substance use motives, results suggested that COVID-related worry, but not fear, was associated with coping motives. Although somewhat surprising, these results are in line with past work suggesting that worry, but not fear, is prospectively associated with affect-oriented substance use ([@bib0041]). Additionally, previous social anxiety-substance use models suggest that future oriented fear, or worry, is associated with substance use ([@bib0007]). Therefore, it is possible that, when both worry and fear are considered together, individuals may be using substances because they are worried about the future more than the current situation (i.e., worry being more prominent than fear).

The results of this study may have important clinical implications. COVID-19 has been associated with a drastic increase in mental health service utilization ([@bib0027]a). Given the observed difference in COVID-19-related worry and fear, assessing these constructs in a clinical context may shed light on those at highest risk for substance use, and ultimately, substance use problems. By identifying these individuals early, clinicians may implement prevention efforts to reduce consequences associated with affect-oriented coping in response to COVID-19. As the outbreak continues to evolve, it may be important to develop targeted interventions for COVID-19-specific mental health and substance use problems.

The current study does have limitations that warrant comment. First, the data are cross sectional, prohibiting causal and temporal claims about risk factors for substance use initiation. Future studies examining these associations over time is warranted. Additionally, substance use was assessed using self-report measures. Replicating the findings using complementary substance use screening measures (i.e., urine toxicology) may help to offer a more complete analysis of the mental health-substance use patterns. Further, the sample was largely White, non-Hispanic, and highly educated, which may not be indicative of the most vulnerable individuals ([@bib0051]). Thus, replicating the findings across more diverse groups will increase the generalizability of the findings. It is also possible that the current study was underpowered to detect the statistically significant effects, particularly given the sample size of each group ([@bib0001]; [@bib0029]). Additionally, it is important to note that, while *Hedge\'s g* is an appropriate measure of effect size with unequal sample sizes and small sample sizes, it is possible these estimates are biased. Although it is important to replicate and extend the findings from the current study with larger samples, previous research argues that effect size estimates are central to understanding *how* different groups are, and offers a comprehensive point of analysis ([@bib0043]). Finally, the sample was unselected in terms of COVID-19 symptoms and diagnosis, and only a small number of participants in the current study endorsed symptoms and/or diagnosis. It is possible that the relationship between worry, fear, and substance use may differ among those who have had symptoms of the virus compared to those who have not, and future research in this area may be fruitful.

Overall, the current study evaluated if COVID-19-related worry and fear differed between substance abstainers, pre-COVID-19 users, and COVID-19 initiators, and if these constructs were associated with coping-related motives for substance use. Results generally suggest the COVID-19 initiators evince the highest levels of COVID-19-related worry and fear. Additionally, worry, but not fear, appears to be associated with substance use motives. These results provide preliminary evidence that COVID-19-related worry and fear may be putative risk factors for substance use initiation in the face of COVID-19, and these results may provide critical clinical information for helping individuals cope with this pandemic.
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